Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177193 | 0.87 | THRA (0.56) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3389485 | 0.86 | CREBBP (0.66) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1932820 | 0.86 | TSHR (0.66) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9622873 | 0.86 | F2 (0.56) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL11364819 | 0.85 | THRA (0.66) | TSHRMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL27459572 | 0.85 | MAPK1 (0.67) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6246000 | 0.85 | MAPT (0.57) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6244283 | 0.84 | MAPT (0.83) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5340855 | 0.84 | TSHR (0.68) | TSHRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9638859 | 0.84 | THRA (0.68) | TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103193633-A | Preparation and application of 3-bromo-4-ethoxybenzoic acid | UNIV QINGDAO AGRICULTURAL | 2013-07-10 | — | — | CN | claimed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-103193633-A | Preparation and application of 3-bromo-4-ethoxybenzoic acid | UNIV QINGDAO AGRICULTURAL | 2013-07-10 | — | — | CN | disclosed |
| CN-103193633-A | Preparation and application of 3-bromo-4-ethoxybenzoic acid | UNIV QINGDAO AGRICULTURAL | 2013-07-10 | — | — | CN | disclosed |
| WO-2000009486-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | disclosed |
| EP-0971897-A1 | ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-01-19 | — | — | EP | disclosed |
| EP-0968190-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999065903-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999031068-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999021836-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998054184-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998041507-A1 | ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998041508-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, NLRP1, PYCARD | TSHR 4615/4885MAPT 621/4885MEN1 4508/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | TSHR 4549/4885MAPT 432/4885MEN1 4462/4885 |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, CASP1, PYCARD | TSHR 4572/4885MAPT 613/4885MEN1 4523/4885 |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | TSHR 4549/4885MAPT 432/4885MEN1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.